Updates are available Correction dated 2024-05-22
Click to view Correction: https://doi.org/10.1038/s43018-024-00786-1
-
Authors
Rezvan, Ali
Romain, Gabrielle
Fathi, Mohsen
Heeke, Darren
Martinez-Paniagua, Melisa
An, Xingyue https://orcid.org/0000-0001-9912-0683
Bandey, Irfan N.
Montalvo, Melisa J.
Adolacion, Jay R. T.
Saeedi, Arash
Sadeghi, Fatemeh
Fousek, Kristen
Puebla-Osorio, Nahum https://orcid.org/0000-0001-6498-5230
Cooper, Laurence J. N.
Bernatchez, Chantale
Singh, Harjeet https://orcid.org/0000-0001-6314-5790
Ahmed, Nabil
Mattie, Mike
Bot, Adrian
Neelapu, Sattva https://orcid.org/0000-0003-1045-4914
Varadarajan, Navin https://orcid.org/0000-0001-7524-8228
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01GM143243)
Cancer Prevention and Research Institute of Texas (RP180466)
Melanoma Research Alliance (509800)
National Science Foundation (1705464)
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CA160591)
Owens Foundation
- License Information
-
More Information
Article History
Received: 4 May 2023
Accepted: 10 April 2024
First Online: 15 May 2024
Change Date: 22 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-024-00786-1
Competing interests
: L.J.N.C. and N.V. are cofounders of CellChorus that licensed TIMING from University of Houston. N.V. is a cofounder of AuraVax Therapeutics. L.J.N.C. has equity ownership in Alaunos Oncology (formerly Ziopharm Oncology). The Sleeping Beauty system for CD19-specific CAR T cells is licensed including to Ziopharm Oncology. M.F. is an employee of CellChorus. None of these conflicts of interest influenced any part of the study design or results. The remaining authors declare no competing interests.
